ERYTECH Provides Business and Financial Update for the First Half of 2022
ERYTECH Pharma today provided a business and financial update for the first half of 2022.
ERYTECH Provides Regulatory Update
ERYTECH Pharma provided a regulatory update, announcing that it is no longer seeking approval for Graspa® in hypersensitive acute lymphoblastic leukemia (ALL) following feedback from the U.S. Food and Drug…
REPORT – ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 24, 2022
ERYTECH Pharma announced that its Annual General Meeting was held on Friday, June 24, 2022.
ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022
ERYTECH’s shareholders are hereby informed of the Annual General Meeting which will be held on June 24, 2022 at 09:00am CEST at the Hôtel Intercontinental Paris – Le Grand, 2…
ERYTECH to Present at the H.C. Wainwright Global Investment Conference
ERYTECH Pharma announced that its CEO, Gil Beyen, will present at the H.C. Wainwright Global Investment Conference. The conference will be held in a hybrid format from May 23-26, 2022,…
ERYTECH Provides Business and Financial Update for the First Quarter of 2022
ERYTECH Pharma provided a business and financial update at the end of March 2022.
ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar
ERYTECH Pharma announced that it had filed its 2021 Universal Registration Document for the year ended December 31, 2021, including the management report and the annual financial report with the…
ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent
ERYTECH Pharma announced the sale of its U.S. manufacturing facility to Catalent, a leading contract development and manufacturing organization (CDMO) in advanced therapies.
ERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial in Hypersensitive ALL in the British Journal of Haematology
The study confirms the potential of eryaspase (GRASPA®) as an attractive treatment option for acute lymphoblastic leukemia (ALL) patients with hypersensitivity to PEG-asparaginase
ERYTECH to Present Novel Vesiculation Approach at the 24th Meeting of the European Red Cell Society
ERYTECH Pharma announced the presentation of its novel red blood cell vesiculation technology at the 24th Meeting of the European Red Cell Society (ERCS), taking place from April 7 to…